文献速递创伤与烧伤复苏、休克与脓毒症

院前氨甲环酸与创伤后多配体蛋白聚糖-1剂量依赖性降低相关:一项前瞻性随机试验的二次分析

Prehospital tranexamic acid is associated with a dose-dependent decrease in syndecan-1 after trauma: A secondary analysis of a prospective randomized trial.
PubMed 文献 · J Trauma Acute Care Surg · 2023-05-01
一句话结论STAAMP试验二次分析显示,院前氨甲环酸与入院时多配体蛋白聚糖-1降低相关,且12小时多配体蛋白聚糖-1与氨甲环酸剂量呈负相关,提示可能减轻内皮糖萼损伤。

本研究为STAAMP前瞻性随机试验的二次分析,纳入766例患者(安慰剂383例、简化剂量130例、标准剂量119例、重复剂量130例),检测入院时(0小时)及12、24、72小时的内皮功能与组织损伤标志物。结果显示,入院后72小时内较低的多配体蛋白聚糖-1、可溶性血栓调节蛋白和血小板内皮细胞黏附分子-1水平与30天生存相关(p < 0.001)。入院时氨甲环酸组多配体蛋白聚糖-1较低(28.30 [20.05, 42.75] vs. 33.50 [23.00, 54.00],p = 0.001),控制患者、损伤及院前因素后仍显著(p = 0.001)。院前转运及入院后前8小时内每增加1 g氨甲环酸,12小时多配体蛋白聚糖-1降低4 ng/mL(p = 0.03)。作者认为早期院前及院内氨甲环酸可能以剂量依赖方式减轻内皮糖萼损伤或上调血管修复机制。

要点

  • 在STAAMP试验全部766例患者中,入院后72小时内较低的多配体蛋白聚糖-1、可溶性血栓调节蛋白和血小板内皮细胞黏附分子-1水平与30天生存相关(p < 0.001)。
  • 入院时氨甲环酸组多配体蛋白聚糖-1低于安慰剂组(28.30 [20.05, 42.75] vs. 33.50 [23.00, 54.00],p = 0.001),控制患者、损伤及院前因素后仍显著(p = 0.001)。
  • 院前转运及入院后前8小时内每增加1 g氨甲环酸,12小时多配体蛋白聚糖-1降低4 ng/mL(p = 0.03),控制患者、损伤及治疗因素后。
  • 作者认为早期院前及院内氨甲环酸可能以剂量依赖方式减轻内皮糖萼损伤或上调血管修复机制。

适用人群与场景

  • STAAMP试验纳入的全部患者,共766例:安慰剂组383例、简化剂量组130例、标准剂量组119例、重复剂量组130例。

研究设计与关键结果

  • 研究类型:STAAMP前瞻性随机试验的二次分析;样本量766例(安慰剂383例、简化剂量130例、标准剂量119例、重复剂量130例);检测入院时(0小时)及12、24、72小时的多配体蛋白聚糖-1、可溶性血栓调节蛋白和血小板内皮细胞黏附分子-1。
  • 入院后72小时内较低的多配体蛋白聚糖-1、可溶性血栓调节蛋白和血小板内皮细胞黏附分子-1水平与30天生存相关(p < 0.001)。
  • 入院时多配体蛋白聚糖-1:氨甲环酸组28.30(20.05, 42.75)vs. 安慰剂组33.50(23.00, 54.00),p = 0.001;控制患者、损伤及院前因素后p = 0.001。
  • 院前转运及入院后前8小时内每增加1 g氨甲环酸,12小时多配体蛋白聚糖-1降低4 ng/mL(p = 0.03),控制患者、损伤及治疗因素。

证据类型、等级与局限

  • 证据类型:前瞻性随机试验的二次分析;证据等级:治疗/护理管理;Level III。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为早期院前及院内氨甲环酸可能以剂量依赖方式减轻内皮糖萼损伤或上调血管修复机制。

指南或共识出处

  • Study of Tranexamic Acid During Air and Ground Prehospital Transport (STAAMP) Trial

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In the Study of Tranexamic Acid During Air and Ground Prehospital Transport (STAAMP) Trial, prehospital tranexamic acid (TXA) was associated with lower mortality in specific patient subgroups. The underlying mechanisms responsible for a TXA benefit remain incompletely characterized. We hypothesized that TXA may mitigate endothelial injury and sought to assess whether TXA was associated with decreased endothelial or tissue damage markers among all patients enrolled in the STAAMP Trial.

METHODS: We collected blood samples from STAAMP Trial patients and measured markers of endothelial function and tissue damage including syndecan-1, soluble thrombomodulin (sTM), and platelet endothelial cell adhesion molecule-1 at hospital admission (0 hours) and 12 hours, 24 hours, and 72 hours after admission. We compared these marker values for patients in each treatment group during the first 72 hours, and modeled the relationship between TXA and marker concentration using regression analysis to control for potential confounding factors.

RESULTS: We analyzed samples from 766 patients: 383 placebo, 130 abbreviated dosing, 119 standard dosing, and 130 repeat dosing. Lower levels of syndecan-1, TM, and platelet endothelial cell adhesion molecule measured within the first 72 hours of hospital admission were associated with survival at 30 days ( p < 0.001). At hospital admission, syndecan-1 was lower in the TXA group (28.30 [20.05, 42.75] vs. 33.50 [23.00, 54.00] p = 0.001) even after controlling for patient, injury, and prehospital factors ( p = 0.001). For every 1 g increase in TXA administered over the first 8 hours of prehospital transport and hospital admission, there was a 4-ng/mL decrease in syndecan-1 at 12 hours controlling for patient, injury, and treatment factors ( p = 0.03).

CONCLUSION: Prehospital TXA was associated with decreased syndecan-1 at hospital admission. Syndecan-1 measured 12 hours after admission was inversely related to the dose of TXA received. Early prehospital and in-hospital TXA may decrease endothelial glycocalyx damage or upregulate vascular repair mechanisms in a dose-dependent fashion.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Gruen DS, Brown JB, Guyette FX, et al. Prehospital tranexamic acid is associated with a dose-dependent decrease in syndecan-1 after trauma: A secondary analysis of a prospective randomized trial. J Trauma Acute Care Surg. 2023. PMID: 37125811. doi:10.1097/TA.0000000000003955

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。